Pfizer CEO Says Covid Is ‘Irrelevant.’ He’s Betting on Cancer and Weight-Loss Drugs.
Pfizer increased its 2026 forecast due to strong sales of newer products, including cancer and weight-loss drugs. The company's blood thinner drug, Eliquis, also drove the Q3 beat. Pfizer CEO Albert Bourla is betting on these new products to drive growth post-pandemic. The company raised its full-year outlook and appointed a new CFO, Cecile Guegan.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Pfizer raised its 2026 forecast due to strong sales of newer products.
- ✓ Pfizer's blood thinner drug, Eliquis, drove the Q3 beat.
- ✓ Pfizer appointed Cecile Guegan as its new CFO.
- ✓ Pfizer CEO Albert Bourla is betting on new products, including cancer and weight-loss drugs, to drive growth post-pandemic.
What changed
Pfizer raised its 2026 forecast and appointed a new CFO, Cecile Guegan, as the company continues to shift its focus towards newer products.
Live updates
-
Pfizer Raises 2026 Forecast on New Product Growth
Pfizer increased its 2026 forecast due to strong sales of newer products, including cancer and weight-loss drugs. The company's blood thinner drug, Eliquis, also drove the Q3 beat. Pfizer CEO Albert Bourla is betting on these new products to drive growth post-pandemic. The company raised its full-year outlook and appointed a new CFO, Cecile Guegan.
Why it matters
Pfizer's growth strategy focuses on new products, including cancer and weight-loss drugs, as COVID-19 sales decline. The company's Q3 results beat expectations, driven by Eliquis and other newer products. This momentum is expected to continue, with Pfizer raising its 2026 forecast.
What is confirmed
- Pfizer raised its 2026 forecast due to strong sales of newer products.
- Pfizer's blood thinner drug, Eliquis, drove the Q3 beat.
- Pfizer appointed Cecile Guegan as its new CFO.
- Pfizer CEO Albert Bourla is betting on new products, including cancer and weight-loss drugs, to drive growth post-pandemic.
Still unconfirmed
- Pfizer CEO says COVID-19 is 'irrelevant'.
What to watch next
- Pfizer's Q4 2026 earnings report
- FDA approvals for new products
- Competition in the cancer and weight-loss drug markets
confidence 85%Sources used for this update (16)
- CNBC — Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
- Reuters — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat
- Bloomberg — Pfizer Raises 2026 Forecast, Extending Big Pharma Windfall
- Yahoo Finance — Pfizer increases annual profit forecast amid solid demand for blood thinner drug
- WSJ — Pfizer Raises Forecast on Momentum With New Products
- Barron's — Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act
- Fierce Pharma — Pfizer delivers Q3 beat as post-COVID comeback gains momentum
- Yahoo Finance — Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
- Yahoo Finance — Pfizer earnings analysis: questions answered and next catalysts
- CNBC — Pfizer hikes full-year outlook on new product growth, taps company veteran as new CFO
- Morningstar — Pfizer Earnings: Our Pipeline View Is Incrementally Positive
- Barron's — Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community